Epitope-based Vaccine Design for California Encephalitis Virus(Cev) : a Computational Study Targeting Membrane Glycoproteins

Abstract

California encephalitis is an uncommon viral brain infection that is caused by the California encephalitis virus (CEV).With encephalitis, the majority of patients experience full recovery with a mortality rate of less than 1%. A 20% or higher percentage of patients experience recurring seizures or behavioural issues. There is currently no vaccine or prescribed medication for California encephalitis, an infectious disease that is on the rise. Therefore, the development of a novel vaccination against CEV is imperative. The current study develops a vaccine based on many epitopes using immunoinformatic methods. B and T cell epitopes were predicted using the CEV membrane glycoprotein polyprotein as a target protein. The predicted T- and B-cell epitopes were then examined for conservancy, toxicity, allergenicity, and immunogenicity. HLA alleles were paired with screened epitopes to make sure they interacted to trigger an immune response. The best selected epitopes were used to create the vaccine. Studying the vaccine's physicochemical qualities and other features revealed its immunogenicity, stability, and safety. Afterwards, two Toll-like receptor-8 (TLR-8) was docked with the vaccination, and molecular dynamic simulations were examined. To ensure that the vaccine's codons would express themselves efficiently in a plasmid vector for in silico cloning tests, more codon adaptation of the vaccine sequence was carried out. It is predicted that the vaccine developed for this study will demonstrate its efficacy in controlling and preventing CEV .To make sure it's safe and effective, more in vivo and in vitro research needs to be done.